Colorado State University Develops Tuberculosis Vaccine
A Colorado State University (Fort Collins, CO, www.colostate.edu) research team has developed a novel vaccine to prevent tuberculosis (TB).
A Colorado State University (Fort Collins, CO, www.colostate.edu) research team has developed a novel vaccine to prevent tuberculosis (TB). The vaccine triggers the body’s immunity in a novel way by activating specific immune system functions that enhance the response to the bacterium that causes tuberculosis. Although in preliminary stages of testing, the vaccine would likely be effective against all strains of TB, including multidrug and extensively drug-resistant tuberculosis. Preliminary evidence shows that the vaccine has promise of working after exposure to TB, which no other vaccine in current development has achieved. The vaccine is designed to be relatively easy to produce. Human trials for the vaccine could occur in two to three years.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
